Thymoglobulin, interferon-γ and interleukin-2 efficiently expand cytokine-induced killer (CIK) cells in clinical-grade cultures

Journal of Translational Medicine

Volumn 8, Issue , 2010, Pages

  Bonanno, Giuseppina ^a,b   Iudicone, Paola ^b   Mariotti, Andrea ^a   Procoli, Annabella ^a   Pandolfi, Annino ^b   Fioravanti, Daniela ^b   Corallo, Maria ^a   Perillo, Alessandro ^a   Scambia, Giovanni ^a   Pierelli, Luca ^b,c   Rutella, Sergio ^a,d  

^a CATHOLIC UNIVERSITY   (Italy)

^b SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d IRCCS SAN RAFFAELE PISANA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CD94 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 12P40; INTERLEUKIN 2; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 2DL1; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 2DL2; MONOCLONAL ANTIBODY CD3; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 1; NATURAL KILLER CELL ACTIVATING RECEPTOR; NATURAL KILLER CELL INHIBITORY RECEPTOR; NATURAL KILLER CELL RECEPTOR; NATURAL KILLER CELL RECEPTOR NKG2A; NATURAL KILLER CELL TRIGERRING RECEPTOR; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG; LYMPHOCYTE ANTIBODY;

ADULT; ARTICLE; CANCER PATIENT; CELL CULTURE; CELL CULTURE MONITORING; CELL EXPANSION; CELL STIMULATION; CELL STRAIN K 562; CHRONIC MYELOID LEUKEMIA; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE INDUCED KILLER CELL; CYTOLYSIS; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; LEUKEMIA CELL LINE; NATURAL KILLER CELL MEDIATED CYTOTOXICITY; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REGULATORY T LYMPHOCYTE; SOLID TUMOR; TUMOR IMMUNITY; ANIMAL; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; CULTURE TECHNIQUE; CYTOLOGY; CYTOTOXICITY; DONOR; DRUG EFFECT; IMMUNOLOGY; METHODOLOGY; MIDDLE AGED; NATURAL KILLER CELL; NEOPLASM; PHENOTYPE; RABBIT;

ADULT; ANIMALS; ANTILYMPHOCYTE SERUM; CD8-POSITIVE T-LYMPHOCYTES; CELL CULTURE TECHNIQUES; CELL PROLIFERATION; CELLS, CULTURED; CYTOKINE-INDUCED KILLER CELLS; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-2; KILLER CELLS, NATURAL; MIDDLE AGED; NEOPLASMS; PHENOTYPE; RABBITS; T-LYMPHOCYTES, REGULATORY; TISSUE DONORS; YOUNG ADULT;

EID: 78649732786     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-8-129     Document Type: Article

References (49)

1. Grimm EA, Mazumder A, Zhang HZ, Rosenberg SA. Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. J Exp Med 1982, 155:1823-1841. 10.1084/jem.155.6.1823, 2186695, 6176669.
2. Phillips JH, Lanier LL. Dissection of the lymphokine-activated killer phenomenon. Relative contribution of peripheral blood natural killer cells and T lymphocytes to cytolysis. J Exp Med 1986, 164:814-825. 10.1084/jem.164.3.814, 2188384, 3489062.
3. Introna M, Borleri G, Conti E, Franceschetti M, Barbui AM, Broady R, Dander E, Gaipa G, D'Amico G, Biagi E, et al. Repeated infusions of donor-derived cytokine-induced killer cells in patients relapsing after allogeneic stem cell transplantation: a phase I study. Haematologica 2007, 92:952-959. 10.3324/haematol.11132, 17606446.
4. Schmidt-Wolf IG, Negrin RS, Kiem HP, Blume KG, Weissman IL. Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity. J Exp Med 1991, 174:139-149. 10.1084/jem.174.1.139, 2118875, 1711560.
5. Mehta BA, Schmidt-Wolf IG, Weissman IL, Negrin RS. Two pathways of exocytosis of cytoplasmic granule contents and target cell killing by cytokine-induced CD3+CD56+ killer cells. Blood 1995, 86:3493-3499.
6. Verneris MR, Karami M, Baker J, Jayaswal A, Negrin RS. Role of NKG2D signaling in the cytotoxicity of activated and expanded CD8+ T cells. Blood 2004, 103:3065-3072. 10.1182/blood-2003-06-2125, 15070686.
7. Verneris MR, Ito M, Baker J, Arshi A, Negrin RS, Shizuru JA. Engineering hematopoietic grafts: purified allogeneic hematopoietic stem cells plus expanded CD8+ NK-T cells in the treatment of lymphoma. Biol Blood Marrow Transplant 2001, 7:532-542. 10.1016/S1083-8791(01)70014-6, 11760085.
8. Kim HM, Lim J, Kang JS, Park SK, Lee K, Kim JY, Kim YJ, Hong JT, Kim Y, Han SB. Inhibition of human cervical carcinoma growth by cytokine-induced killer cells in nude mouse xenograft model. Int Immunopharmacol 2009, 9:375-380. 10.1016/j.intimp.2008.12.001, 19105981.
9. Sweeney TJ, Mailander V, Tucker AA, Olomu AB, Zhang W, Cao Y, Negrin RS, Contag CH. Visualizing the kinetics of tumor-cell clearance in living animals. Proc Natl Acad Sci USA 1999, 96:12044-12049. 10.1073/pnas.96.21.12044, 18409, 10518573.
10. Hontscha C, Borck Y, Zhou H, Messmer D, Schmidt-Wolf IG. Clinical trials on CIK cells: first report of the international registry on CIK cells (IRCC). J Cancer Res Clin Oncol 2010,
11. Leemhuis T, Wells S, Scheffold C, Edinger M, Negrin RS. A phase I trial of autologous cytokine-induced killer cells for the treatment of relapsed Hodgkin disease and non-Hodgkin lymphoma. Biol Blood Marrow Transplant 2005, 11:181-187. 10.1016/j.bbmt.2004.11.019, 15744236.
12. Olioso P, Giancola R, Di Riti M, Contento A, Accorsi P, Iacone A. Immunotherapy with cytokine induced killer cells in solid and hematopoietic tumours: a pilot clinical trial. Hematol Oncol 2009, 27:130-139. 10.1002/hon.886, 19294626.
13. Deeks ED, Keating GM. Rabbit antithymocyte globulin (thymoglobulin): a review of its use in the prevention and treatment of acute renal allograft rejection. Drugs 2009, 69:1483-1512. 10.2165/00003495-200969110-00007, 19634926.
14. Myint AA, Malkovska V, Morgan S, Luckit J, Wonke B, Gordon-Smith EC. Antilymphocyte globulin therapy enhances impaired function of natural killer cells and lymphokine activated killer cells in aplastic anaemia. Br J Haematol 1990, 75:578-584. 10.1111/j.1365-2141.1990.tb07802.x, 2207010.
15. Rutella S, Pierelli L, Bonanno G, Sica S, Ameglio F, Capoluongo E, Mariotti A, Scambia G, d'Onofrio G, Leone G. Role for granulocyte colony-stimulating factor in the generation of human T regulatory type 1 cells. Blood 2002, 100:2562-2571. 10.1182/blood-2001-12-0291, 12239170.
16. Rutella S, Pierelli L, Bonanno G, Mariotti A, Sica S, Sora F, Chiusolo P, Scambia G, Rumi C, Leone G. Immune reconstitution after autologous peripheral blood progenitor cell transplantation: effect of interleukin-15 on T-cell survival and effector functions. Exp Hematol 2001, 29:1503-1516. 10.1016/S0301-472X(01)00747-0, 11750110.
17. Rutella S, Bonanno G, Procoli A, Mariotti A, de Ritis DG, Curti A, Danese S, Pessina G, Pandolfi S, Natoni F, et al. Hepatocyte growth factor favors monocyte differentiation into regulatory interleukin (IL)-10++IL-12low/neg accessory cells with dendritic-cell features. Blood 2006, 108:218-227. 10.1182/blood-2005-08-3141, 16527888.
18. Cholujova D, Jakubikova J, Kubes M, Arendacka B, Sapak M, Ihnatko R, Sedlak J. Comparative study of four fluorescent probes for evaluation of natural killer cell cytotoxicity assays. Immunobiology 2008, 213:629-640. 10.1016/j.imbio.2008.02.006, 18765168.
19. Rutella S, Bonanno G, Marone M, De Ritis D, Mariotti A, Voso MT, Scambia G, Mancuso S, Leone G, Pierelli L. Identification of a novel subpopulation of human cord blood CD34-CD133-CD7-CD45+lineage- cells capable of lymphoid/NK cell differentiation after in vitro exposure to IL-15. J Immunol 2003, 171:2977-2988.
20. Lecoeur H, de Oliveira-Pinto LM, Gougeon ML. Multiparametric flow cytometric analysis of biochemical and functional events associated with apoptosis and oncosis using the 7-aminoactinomycin D assay. J Immunol Methods 2002, 265:81-96. 10.1016/S0022-1759(02)00072-8, 12072180.
21. Kim GG, Donnenberg VS, Donnenberg AD, Gooding W, Whiteside TL. A novel multiparametric flow cytometry-based cytotoxicity assay simultaneously immunophenotypes effector cells: comparisons to a 4 h 51Cr-release assay. J Immunol Methods 2007, 325:51-66. 10.1016/j.jim.2007.05.013, 2040258, 17617419.
22. Bonanno G, Procoli A, Mariotti A, Corallo M, Perillo A, Danese S, De Cristofaro R, Scambia G, Rutella S. Effects of pegylated G-CSF on immune cell number and function in patients with gynecological malignancies. J Transl Med 2010, 8:114. 10.1186/1479-5876-8-114, 2992497, 21062439.
23. Liu Z, Fang Y, Wang X, Wang P, Yun P, Xu H. Upregulation of molecules associated with T-regulatory function by thymoglobulin pretreatment of human CD4+ cells. Transplantation 2008, 86:1419-1426. 10.1097/TP.0b013e318187c2e5, 19034013.
24. Malek TR, Bayer AL. Tolerance, not immunity, crucially depends on IL-2. Nat Rev Immunol 2004, 4:665-674. 10.1038/nri1435, 15343366.
25. Ahmadzadeh M, Rosenberg SA. IL-2 administration increases CD4+CD25hiFoxp3+ regulatory T cells in cancer patients. Blood 2006, 107:2409-2414. 10.1182/blood-2005-06-2399, 1473973, 16304057.
26. Wei S, Kryczek I, Edwards RP, Zou L, Szeliga W, Banerjee M, Cost M, Cheng P, Chang A, Redman B, et al. Interleukin-2 administration alters the CD4+FoxP3+ T-cell pool and tumor trafficking in patients with ovarian carcinoma. Cancer Res 2007, 67:7487-7494. 10.1158/0008-5472.CAN-07-0565, 17671219.
27. Linn YC, Hui KM. Cytokine-induced NK-like T cells: from bench to bedside. J Biomed Biotechnol 2010, 2847766, 20368995.
28. Ayello J, van de Ven C, Cairo E, Hochberg J, Baxi L, Satwani P, Cairo MS. Characterization of natural killer and natural killer-like T cells derived from ex vivo expanded and activated cord blood mononuclear cells: implications for adoptive cellular immunotherapy. Exp Hematol 2009, 37:1216-1229. 10.1016/j.exphem.2009.07.009, 19638292.
29. D'Andrea A, Rengaraju M, Valiante NM, Chehimi J, Kubin M, Aste M, Chan SH, Kobayashi M, Young D, Nickbarg E, et al. Production of natural killer cell stimulatory factor (interleukin 12) by peripheral blood mononuclear cells. J Exp Med 1992, 176:1387-1398. 2119437, 1357073.
30. Beyer M, Schultze JL. Regulatory T cells in cancer. Blood 2006, 108:804-811. 10.1182/blood-2006-02-002774, 16861339.
31. Dunne J, Lynch S, O'Farrelly C, Todryk S, Hegarty JE, Feighery C, Doherty DG. Selective expansion and partial activation of human NK cells and NK receptor-positive T cells by IL-2 and IL-15. J Immunol 2001, 167:3129-3138.
32. Franceschetti M, Pievani A, Borleri G, Vago L, Fleischhauer K, Golay J, Introna M. Cytokine-induced killer cells are terminally differentiated activated CD8 cytotoxic T-EMRA lymphocytes. Exp Hematol 2009, 37:616-628. e612, 10.1016/j.exphem.2009.01.010, 19375652.
33. Lu PH, Negrin RS. A novel population of expanded human CD3+CD56+ cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency. J Immunol 1994, 153:1687-1696.
34. Hoyle C, Bangs CD, Chang P, Kamel O, Mehta B, Negrin RS. Expansion of Philadelphia chromosome-negative CD3+CD56+ cytotoxic cells from chronic myeloid leukemia patients: in vitro and in vivo efficacy in severe combined immunodeficiency disease mice. Blood 1998, 92:3318-3327.
35. Dalle JH, Dardari R, Menezes J, Cordeiro P, Champagne MA, Duval M. Binding of thymoglobulin to natural killer cells leads to cell activation and interferon-γ production. Transplantation 2009, 87:473-481. 10.1097/TP.0b013e3181949c57, 19307782.
36. Penack O, Fischer L, Gentilini C, Nogai A, Muessig A, Rieger K, Ganepola S, Thiel E, Uharek L. The type of ATG matters -- natural killer cells are influenced differentially by Thymoglobulin, Lymphoglobulin and ATG-Fresenius. Transpl Immunol 2007, 18:85-87. 10.1016/j.trim.2007.05.001, 18005849.
37. Makrigiannis AP, Anderson SK. Regulation of natural killer cell function. Cancer Biol Ther 2003, 2:610-616.
38. Mingari MC, Schiavetti F, Ponte M, Vitale C, Maggi E, Romagnani S, Demarest J, Pantaleo G, Fauci AS, Moretta L. Human CD8+ T lymphocyte subsets that express HLA class I-specific inhibitory receptors represent oligoclonally or monoclonally expanded cell populations. Proc Natl Acad Sci USA 1996, 93:12433-12438. 10.1073/pnas.93.22.12433, 38009, 8901599.
39. Vely F, Peyrat M, Couedel C, Morcet J, Halary F, Davodeau F, Romagne F, Scotet E, Saulquin X, Houssaint E, et al. Regulation of inhibitory and activating killer-cell Ig-like receptor expression occurs in T cells after termination of TCR rearrangements. J Immunol 2001, 166:2487-2494.
40. Li G, Yu M, Weyand CM, Goronzy JJ. Epigenetic regulation of killer immunoglobulin-like receptor expression in T cells. Blood 2009, 114:3422-3430. 10.1182/blood-2009-01-200170, 2765678, 19628706.
41. Arlettaz L, Degermann S, De Rham C, Roosnek E, Huard B. Expression of inhibitory KIR is confined to CD8+ effector T cells and limits their proliferative capacity. Eur J Immunol 2004, 34:3413-3422. 10.1002/eji.200324756, 15549734.
42. Bonanno G, Mariotti A, Procoli A, Corallo M, Scambia G, Pierelli L, Rutella S. Interleukin-21 induces the differentiation of human umbilical cord blood CD34-lineage- cells into pseudomature lytic NK cells. BMC Immunology 2009, 10:46. 10.1186/1471-2172-10-46, 2743656, 19712464.
43. Eagle RA, Trowsdale J. Promiscuity and the single receptor: NKG2D. Nat Rev Immunol 2007, 7:737-744. 10.1038/nri2144, 17673918.
44. Kaiser BK, Pizarro JC, Kerns J, Strong RK. Structural basis for NKG2A/CD94 recognition of HLA-E. Proc Natl Acad Sci USA 2008, 105:6696-6701. 10.1073/pnas.0802736105, 2373352, 18448674.
45. Borrego F, Masilamani M, Kabat J, Sanni TB, Coligan JE. The cell biology of the human natural killer cell CD94/NKG2A inhibitory receptor. Mol Immunol 2005, 42:485-488. 10.1016/j.molimm.2004.07.031, 15607803.
46. Gunturi A, Berg RE, Forman J. The role of CD94/NKG2 in innate and adaptive immunity. Immunol Res 2004, 30:29-34. 10.1385/IR:30:1:029, 15258309.
47. Vitale M, Bottino C, Sivori S, Sanseverino L, Castriconi R, Marcenaro E, Augugliaro R, Moretta L, Moretta A. NKp44, a novel triggering surface molecule specifically expressed by activated natural killer cells, is involved in non-major histocompatibility complex-restricted tumor cell lysis. J Exp Med 1998, 187:2065-2072. 10.1084/jem.187.12.2065, 2212362, 9625766.
48. Moretta L, Moretta A. Unravelling natural killer cell function: triggering and inhibitory human NK receptors. EMBO J 2004, 23:255-259. 10.1038/sj.emboj.7600019, 1271745, 14685277.
49. Trinchieri G, Pflanz S, Kastelein RA. The IL-12 family of heterodimeric cytokines: new players in the regulation of T cell responses. Immunity 2003, 19:641-644. 10.1016/S1074-7613(03)00296-6, 14614851.